Clinical trials: Patient With Colorectal Cancer
Colorectal Cancer
Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer
The FC-7 study is designed as an open label, single arm, Phase I/II dose-escalation study evaluating the combination of neratinib and cetuximab in patients with metastatic colorectal cancer primary tumor that is "quadruple…
- Trial name
- NCT01960023
- Testing
- Cetuximab, Neratinib
- Where
- 12 sites in United States
- Sponsor
- NSABP Foundation Inc
Colorectal Cancer Metastatic
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Microdevices have been used to ascertain in vivo drug response, which can lead to improved cancer treatment delivery; however, they have not been evaluated for liver tumors.
- Trial name
- NCT07193862
- Testing
- Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Colorectal Cancer
An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Colorectal Cancer (CRONOS 1)
This single arm, prospective, observational study will assess the correlation between the time from start of chemotherapy to the start of Avastin (bevacizumab) treatment with progression-free survival in patients with previously…
- Trial name
- NCT01277120
- Where
- Romania
- Volunteers
- 174 people
- Sponsor
- Hoffmann-La Roche
Carcinoma of the Appendix, Colorectal Cancer
Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Carcinoma of the Appendix, Colorectal Cancer, Small Intestine Cancer
- Trial name
- NCT00019773
- Testing
- capecitabine, oxaliplatin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
The aim of this multicenter randomized phase II trial is to determine the efficacy of sorafenib and irinotecan combination versus irinotecan monotherapy or versus sorafenib monotherapy in metastatic colorectal cancer patients…
- Trial name
- NEXIRI2 (NCT01715441)
- Testing
- Sorafenib and irinotecan combination, Sorafenib monotherapy, Irinotecan monotherapy
- Where
- 9 sites in France
- Volunteers
- 173 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Unresectable Colorectal Cancer
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
To confirm the tolerability and safety of combined administration of ONO-7913, ONO-4538 and the standard of care FOLFOX in combination with bevacizumab or cetuximab as first-line treatment in patients with unresectable advanced…
- Trial name
- NCT06540261
- Testing
- ONO-7913, ONO-4538, Fluorouracil
- Where
- 17 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Colorectal Cancer Stage II
First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer
Bevacizumab in combination with chemotherapy represents a standard of care for first-line treatment in patients with advanced colorectal cancer.
- Trial name
- CENTRAL (NCT01853813)
- Testing
- Bevacizumab and FOLFIRI
- Where
- 13 sites in Italy
- Volunteers
- 85 people
- Sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Recurrent Colon Cancer, Recurrent Rectal Cancer
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
This phase I/II trial is studying the side effects and best dose of sorafenib when given together with cetuximab and irinotecan and to see how well they work in treating patients with advanced or metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer
- Trial name
- NCT00134069
- Testing
- sorafenib tosylate, cetuximab, irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Curative Proton Beam Therapy for Patients With Liver Metastasis of Colorectal Cancer
Proton alone therapy is performed -> 5 times a week, 7200 cGy / 15 fractions for 3 weeks total
- Trial name
- NCT03577665
- Testing
- curative proton therapy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- National Cancer Center, Korea
Serrated Polyp, Colorectal Neoplasms
Increasing Serrated Polyp Detection With a Brief Awareness Training
In this non-randomized controlled trial, a semi-random group of Dutch endoscopist receive an oral training about the significance of serrated polyps.
- Trial name
- NCT03902899
- Testing
- Educational intervention (oral presentation)
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Colorectal Cancer
Construction and Empirical Research of the Applicable Baduanjin Protocol for Patients With Colorectal Cancer Enterostomy
The goal of this clinical trial is to understand the application effect of the applicable version of Baduanjin protocol in patients with enterostomy and verify the safety and efficacy of this protocol.
- Trial name
- NCT07172087
- Testing
- Baduanjin for patients with enterostomy
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Locally Advanced Rectal Cancer
Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer
This study aims to investigate the feasibility, safety and efficacy of triplet regimen of neoadjuvant chemotherapy in patients with locally advanced rectal cancer
- Trial name
- NCT03443661
- Testing
- FOLFOXIRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Aiping Zhou
Metastatic Colorectal Cancer
Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer
The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI ( irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients.
- Trial name
- NCT02605044
- Testing
- Masitinib (AB1010), FOLFIRI
- Where
- 3 sites in France, Singapore and 1 more
- Volunteers
- 123 people
- Sponsor
- AB Science
Colorectal Neoplasms
The Role of the Tumor Molecular Profile (CMS), UGT1A1 Genotype and Beta-glucuronidase Activity of the Intestinal Microbiota for Treatment Efficiency, Toxicity, Survival and Quality of Life in Patients With Metastatic or Unresectable Colorectal Cancer During Irinotecan-based Systemic Treatment
Irinotecan-based systemic therapy is a treatment option for metastatic or unresectable colorectal cancer. However, this therapy has two major disadvantages, namely, an unpredictable response to the treatment and severe side…
- Trial name
- OPTIMA (NCT05655780)
- Where
- Netherlands
- Volunteers
- 104 people
- Sponsor
- Maastricht University Medical Center
Stage III Colon Cancer
Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer
This is a pilot study to evaluate the safety of a vaccine that consists of an alphavirus replicon (VRP) encoding the protein (CEA) that has been found to be associated with cancers such as colon cancer in patients that have stage…
- Trial name
- NCT01890213
- Testing
- AVX701
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Duke University
Peritoneum Cancer, Peritoneum Neoplasm
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Multicentric, international, web-based prospective documentation of the indications and results of Pressurized Aerosol Chemotherapy (so-called PIPAC or PITAC) for treating malignant pleural and peritoneal diseases.
- Conditions
- Peritoneum Cancer, Peritoneum Neoplasm, Pleural Cancer, Pleural Effusion
- Trial name
- PIPACRegis (NCT03210298)
- Testing
- PIPAC
- Where
- 16 sites in Argentina, Australia and 11 more
- Volunteers
- 1,000 people
- Sponsor
- Sabine Rhode
Colorectal Cancer, Colon Cancer
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer
The purpose of this study is to evaluate the safety and time to progression of HLA-A*2402 restricted epitope peptides RNF43, TOMM34, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in combination with Tegafur/Uracil/Folinate…
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer
- Trial name
- NCT00677287
- Testing
- RNF43, TOMM34, VEGFR1 and VEGFR2
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Tokyo University
Refractory Metastatic Colorectal Cancer
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus…
- Trial name
- SUNLIGHT (NCT04737187)
- Testing
- Trifluridine/Tipiracil, Bevacizumab
- Where
- 99 sites in United States, Austria and 12 more
- Volunteers
- 492 people
- Sponsor
- Taiho Oncology, Inc.
Colorectal Cancer, Fragility
MPI Predicts Outcome of CRC Elderly Patients (MPI=MULTIDIMENSIONAL PROGNOSTIC INDEX; CRC=COLORECTAL CANCER)
Patients aged ≥75 year scheduled for CRC surgery were studied (104 cases) and variables associated with major postoperative complications / mortality were evaluated.
- Conditions
- Colorectal Cancer, Fragility, Elderly
- Trial name
- MPI;CRC (NCT04594655)
- Testing
- surgery
- Where
- Italy
- Volunteers
- 104 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Digestive Cancer
Association Between Composition of the Gut Microbiota and Nutritional Status in Digestive Oncology
Nutritional status represents a crucial issue in the management of cancer patients, as between 40% and 60% of them suffer from malnutrition at the time of diagnosis.
- Trial name
- ONCONUTRIBIOTA (NCT07260617)
- Testing
- Not applicable- observational study
- Where
- 3 sites in France
- Volunteers
- 150 people
- Sponsor
- Hospices Civils de Lyon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.